Introduction
Combination chemotherapy is the treatment of choice for patients with advanced stage Hodgkin's disease as well as for those who fail attempted curative radiotherapy and 60%-70% of these patients will achieve long term survival or cure [1, 2, 3] . Increasingly, patients with early stage disease with poor prognostic features, such as B-symptoms or bulky mediastinal disease, are also treated with primary chemotherapy or combined modality therapy [4, 5] . The MOPP chemotherapy regimen (mustine, vincristine, procarbazine and prednisolone), introduced 30 years ago, was the first curative regimen for advanced Hodgkin's disease. However, acutely, this treatment caused marked myelosuppression, nausea and vomiting. Secondary myelodysplasia or acute non lymphocytic leukaemia and infertility were well documented long term complications of this regimen [1, [6] [7] [8] . Modifications of MOPP e.g., ChlVPP (chlorambucil, vinblastine, procarbazine and prednisolone) are considered equivalent in efficacy and have less acute toxicity, but long term toxicities, in particular infertility and the increased risk of leukaemia remain a persistent problem [9] .
Several randomised studies have now shown that anthracycline based regimens such as ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) either alone or in combination with MOPP (e.g., MOPP/ABVD or the hybrid regimen MOPP-ABV) improve the failure free survival rates of patients with advanced Hodgkin's disease with some evidence of improvement in cure rates [2, 3, 10] . Of particular importance was the finding in a Cancer and Leukemia Group B (CALGB) study that ABVD given alone for 6-8 months was of equivalent efficacy to MOPP/ABVD and resulted in less toxicity. This regimen is now widely regarded as standard therapy for advanced Hodgkin's disease [2] . However, the morbidity of combination chemotherapy can be considerable, and as the majority of young people treated for Hodgkin's disease are now cured, there is a growing awareness and concern about the late effects of treatment [11] [12] [13] [14] [15] . ABVD is associated with a much lower risk of causing infertility or secondary leukaemia than MOPP or similar regimens [11, 16] . However, acute and chronic cardiac and pulmonary toxicities may occur secondary to doxorubicin and bleomycin, respectively; these are of particular concern when this regimen is used in combination with mediastinal radiotherapy. Most of the long-term toxicities of chemotherapy for Hodgkin's disease are dose related, so reducing the cumulative doses of alkylating agent, doxorubicin and bleomycin should reduce the toxicity of treatment. PACE BOM chemotherapy (prednisolone, doxorubicin, cyclophosphamide, etoposide, bleomycin, vincristine and methotrexate) consists of alternating weekly cycles of myelosuppressive and non myelosuppressive chemotherapy for 12 weeks and incorporates many drugs which are active in Hodgkin's disease with lower cumulative doses of alkylating agent, doxorubicin and bleomycin than given in the MOPP, ABVD, and alternating or hybrid regimens. It was initially developed for the treatment of intermediate grade non-Hodgkin's lymphoma and was well tolerated in this patient population, achieving remission and cure rates comparable to CHOP [17] . A modified form of this regimen has been evaluated in the phase II study described in this paper. This regimen is similar to the Stanford V regimen [18] in brevity, but utilizes different drugs and/or doses and does not include radiotherapy to all sites of initially bulky disease.
Patients and methods

Eligibility and pretreatment evaluation
Between May 1989 and July 1994, all patients aged 14-75 with newly diagnosed biopsy proven advanced Hodgkin's disease (stage IIA with a mediastinal mass > 1/3 of maximum intrathoracic diameter as determined by chest X ray, stage IIB, IIIA and B, IVA and B) or patients with early stage Hodgkin's disease failing initial, attempted curative, treatment with wide field irradiation, were considered for inclusion in this phase II study. These latter patients were restaged and allocated a new Ann Arbor stage at the time of relapse.
Prior to commencing treatment all patients underwent clinical staging consisting of physical examination, full blood count (FBC), erythrocyte sedimentation rate (ESR), serum biochemistry, liver function tests, chest X-ray (CXR), computed tomography (CT) of the chest, abdomen and pelvis and a unilateral posterior iliac crest bone marrow trephine biopsy. Younger patients (age < 40 years) treated at the beginning of the study had serum gonadotropin levels performed; consenting male patients had a sperm count, together with sperm banking when requested and a menstrual history was obtained from female patients.
All biopsy specimens were routinely reviewed by an expert pathologist to confirm the diagnosis of Hodgkin's disease prior to entry of the patient into the study. Patients were required to have a normal FBC, liver and renal function (calculated creatinine clearance >60 ml/min using the Cockroft and Gault formula [19] ), unless the abnormalities found were considered secondary to Hodgkin's disease and thereby reversible with treatment. (Tables I and 2 ) was administered on an outpatient basis for 12 weeks together with prophylactic oral cotrimoxazole. This regimen was identical to that previously described for use in non-Hodgkin's lymphoma [17] , except that the dose of methotrexate was reduced to 50 mg/m 2 All intravenous chemotherapy with the exception of etoposide was given by bolus injection into a peripheral line. Etoposide was diluted in normal saline and administered by infusion over thirty minutes. Haemopoietic growth factors were not administered to any patient during PACE BOM chemotherapy. Omit methotrexate " Creatinine clearance calculated using the Cockcroft-Gault formula [19] Early on in this study patients were re-evaluated clinically and radiologically following both 8 and 12 cycles of PACE BOM. When masses > 2 cm were observed at multiple sites which were noted to be decreasing in size between these evaluations, four further cycles of alternating chemotherapy with PACE BOM were given (only 3 patients received this treatment) Subsequently this approach was abandoned and all patients were treated with 12 cycles of PACE BOM in the absence of disease progression.
Treatment
Chemotherapy
PACE BOM chemotherapy
Radiotherapy
All patients were re-evaluated 3-4 weeks following the completion of chemotherapy. Those with residual mediastinal nodal disease visualised on chest X-ray which could be safely encompassed in a radiotherapy field were treated with mediastinal radiotherapy using anterior and posterior parallel opposed portals to a mid plane dose of 36-40 Gy in 2 Gy fractions (4-6 MeV photons). Additional radiotherapy was given simultaneously to previously noted contiguous sites of nodal diseasemost commonly to unilateral or bilateral cervical regions. No patient received radiation to a field greater than mantle extent and no infradiaphragmatic radiotherapy was used.
Assessment of response
Response to PACE BOM was assessed during and three to four weeks following the completion of chemotherapy and again 3-4 weeks following irradiation when this was employed. Patients with no palpable evidence of Hodgkin's disease and with return to normal of all pre-treatment abnormalities found clinically, radiologically or on bone marrow examination were assessed as achieving a complete response (CR). Patients with a normal CXR but persisting radiological abnor-malities (almost always in the mediastinum) on CT scanning alone were regarded as having an unverified CR (CRu) [20] , If no progression of these abnormalities occurred after one year these patients were then converted to full CR status. Patients with > 50% decrease in the sum of the product of the perpendicular diameters of all measurable lesions were recorded as partial responders (PR), any lesser response was denoted stable disease (SD). Any patient developing disease progression at any site at the time of, or prior to, systematic reevaluation was recorded as progressive disease (PD), regardless of previous response.
Follow-up
Following completion of PACE BOM ± radiotherapy patients were followed two monthly during year 1. three monthly during year 2, four monthly during year 3, six monthly during year 4, then once yearly thereafter. A full physical examination, FBC, ESR and CXR were performed at each evaluation. Persisting abnormalities on CT scan were followed radiologically with repeat scans In young adults (age < 40 years) serum gonadotropin levels were repeated until they stabilised or returned to normal. Menstrual histories were noted, post chemotherapy pregnancies recorded and where possible repeat sperm counts were obtained.
Management of relapse
Clinical or radiological evidence of disease progression was, wherever possible, biopsy proven as being secondary to Hodgkin's disease. Second line therapy was decided on an individual patient basis Selected patients, not previously irradiated and with supradiaphragmatic disease, were managed with mantle radiotherapy The majority, however, were treated with 3-6 cycles of ChlVPP (chlorambucil, vinblastine, procarbazine and predmsolone) chemotherapy alone or supplemented by either involved field radiotherapy or consolidative high dose chemotherapy with autologous bone marrow or peripheral blood stem cell support. Subsequent relapse was managed at the discretion of the involved clinician.
Statistical analysis
The major end points of this study were overall survival (OS) and failure free survival (FFS). Survival and FFS were measured from the date of commencement of PACE BOM. Failure was defined as disease progression at any site or death from any cause. Survival and FFS curves were calculated using the method of Kaplan and Meier [21] .
Results
Patient characteristics
The clinical details of the 83 patients treated with PACE BOM during the period of this study are summarized in Table 3 . The median age of the patients was 29 years (range 14-74). Seventeen patients were stage II with bulky mediastinal disease. In addition, 4 patients with stage III/IV disease had a bulky mediastinal mass. The stage IV sites were bone marrow (4), lung (7), liver (4), bone (1) and adrenal (1) . The median follow up post chemotherapy is 52 months (range 19-86).
Radiotherapy
Sixteen of the patients (19%) had failed previous extended field irradiation at the time of commencement of 21 (25) 49 (59) 76 (92) 5 (6) 2 (2) 57 (89) PACE BOM and none of these received further treatment with radiotherapy. Of the remaining 67 patients 21 (31%) received consolidative irradiation after PACE BOM chemotherapy. The radiotherapy treatment fields in these patients were mediastinum alone (9 patients) mediastinum plus unilateral/bilateral cervical lymph nodes (8 patients) and mantle (4 patients).
Treatment response (Table 4) Thirty five patients achieved complete clinical and radiological remission of their disease following treatment with PACE BOM chemotherapy alone. Following irradiation a further 12 patients achieved CR and a total of 21 patients were recorded as CRu. Of this latter group 17 showed no evidence of disease progression at one year and are therefore regarded as achieving a complete remission (overall CR rate 64/83 patients or 77%). Nine patients achieved a PR after chemotherapy ± irradiation. Six patients developed progressive disease during or shortly after the completion of induction chemotherapy.
Of the 16 patients who were treated with PACE BOM for relapse after previous extended field radiotherapy, 12 achieved a CR, 3 achieved a CRu and remained progression free at one year (overall CR rate 94%) and 1 patient achieved a PR.
The actuarial overall survival and failure-free survival at three years is 92% (confidence intervals 84%-97%) and 68% (57%-77%) and at 5 years is 90% (81%-95%) and 64% (52%-74%) ( Figure 1 ). Figure 2 shows the outcome by stage; the FFS at 5 years is 52% (36%-67%) for stage II, 85% (64%-95%) for stage III and 55% (28%-79%) for stage IV. The 5-year FFS rate for stage III and IV patients combined is 73% (56%-85%).
Disease progression and management
A total of 54 (65%) patients have remained progressionfree after initial chemotherapy ± radiotherapy. Twentynine patients (35%) developed disease progression during or after chemotherapy as follows: (1) progressive disease during treatment -1 patient, (2) relapse < 6 months -9 patients, (3) relapse 6-12 months -8 patients, (4) relapse >12 months -11 patients. The median time to disease progression was 10 months (2-63 months). Of the sixteen patients treated with PACE BOM as salvage therapy following previous radiotherapy only two (13%) have progressed.
Salvage therapy in these 29 cases was radiotherapy alone (3 cases -1 remains progression-free), ChlVPP + /-involved field radiotherapy (12 cases, 6 remain progression-free) and ChlVPP followed by consolidative high-dose chemotherapy with autologous bone marrow or peripheral blood stem cell support (12 cases, 6 remain progression-free). One patient who has recently relapsed has commenced ChlVPP prior to high-dose chemotherapy and one patient left the area and received combination chemotherapy at relapse, remaining progression-free at 38 months after this treatment alone. At present 72 of our patients are alive without disease and 3 are alive with evidence of Hodgkin's disease. There have been a total of 8 deaths (8-65 months post presentation, median 14 months) all of which have been secondary to progressive Hodgkin's disease.
Of the 21 patients who presented with bulky mediastinal disease, 14 (67%) have progressed. Thirteen of these 21 patients (all with stage II disease) received consolidative radiotherapy and 6 of these have relapsed (4 within the radiation field only, one in the radiation field and at other sites simultaneously and one outside the radiation field). Eight patients were not irradiated. In 2 cases a CRu was achieved after PACE BOM so radiotherapy was not given; both have relapsed, one in cervical nodes 2 months after completing treatment and one in cervical nodes and lung 5 years after completing treatment. Three patients achieved a PR to PACE BOM but did not have radiotherapy because of widespread disease in the chest (2 cases) and residual disease in bone marrow (1 case); all have subsequently relapsed. Finally, 3 patients had PD during or immediately after completing PACE BOM.
Toxic ity
PACE BOM was given on an outpatient basis and was generally well tolerated. There were no treatment related deaths. The major toxicities are detailed in Table 5 . Whilst nausea and vomiting occurred, particularly with the ACE chemotherapy, this could almost always be satisfactorily controlled by antiemetic therapy with a 5-HT 3 antagonist with or without dexamethasone. Alopecia occurred universally. Mucositis was also a common problem occurring in 51 (61%) patients. Cutaneous toxicity caused by bleomycin, particularly affecting the (31) 7 (8) 28 (34) 16 (19) 8(10) 0 0 9 (11) 1(1) 0 0 5(6) 1(1) 0 fingers, was a common cause of dose reduction of this drug, occurring in 29 patients (35%) and a number of patients also developed onycholysis after chemotherapy was completed. Twelve patients developed symptoms of peripheral neuropathy secondary to vincristine (maximum WHO grade 2). Vincristine doses were reduced, generally to 1 mg, in these patients all of whom recovered completely. No patients have developed bleomycin related pulmonary fibrosis or clinical evidence of doxorubicin cardiotoxicity. There have been no second malignancies during the limited follow-up period of this study.
Haematological toxicity
Twenty-five patients (30%) required a red cell transfusion (2-5 units) during the course of PACE BOM. No patient required platelet transfusion. Five patients (6%) had a single hospital admission for neutropenic fever and were treated with intravenous antibiotics. One patient developed a clinical picture of opportunistic pneumonia which was successfully treated with intravenous co-trimoxazole. The treating physician had omitted to prescribe prophylactic co-trimoxazole for this patient.
Fertility
Data was available on 28 sequential patients aged under 40 years treated with PACE BOM chemotherapy for 12 weeks +/-radiotherapy alone (i.e., no salvage treatment given) early in this study. Thirteen of these patients were male and post chemotherapy FSH levels were normal in all except one of these patients -this patient had an elevated level 26 months after chemotherapy, however his partner delivered a normal baby 14 months later. Three further live deliveries occurred in the partners of three other patients, and a single ectopic pregnancy also occurred in the partner of a further patient. Sperm counts were available in 6 patients after chemotherapy. In two cases mild oligospermia was present (count 10 x 10 6 /ml), in the remaining four cases counts were normal (42, 60, 60, 80, x 10 6 /ml). Data was available on 15 female patients. Ten pregnancies occurred in seven of these patients resulting in eight live births. A termination of pregnancy was performed in one patient, and one patient is pregnant at the time of this report. In all remaining patients the menstrual cycle has either been unaffected by treatment with PACE BOM or has resumed its previous cycle. 
Dose modifications
Seventy-six patients received 12 cycles of therapy. Three patients received less treatment; one patient receiving only 6 cycles (patient refusal) one 9 cycles (discontinued because of toxicity -patient remains disease free) and one patient 10 cycles (progressive disease). Three patients received 16 treatment cycles as previously discussed and one patient whose treatment was interrupted for some time because of an infective episode also had her treatment extended to 16 weeks. In 13 patients, 12 treatment cycles were given but treatment was delayed (10 patients by a total of one week and in 3 patients by two weeks). A total of 21 patients (25%) received their chemotherapy with no dose reductions or delays. Dose reductions are detailed in Table 6 . The median actual relative dose intensity was ^ 0.91 for each of the individual drugs (range 0.17-1.0).
Discussion
The development of curative combination chemotherapy for patients with advanced Hodgkin's disease is one of the major advances in modern oncology practice. However, the morbidity of prolonged treatment programs extending over 6-12 months for this young patient population can be considerable and may be exacerbated by the addition of consolidative radiotherapy. Furthermore, the late consequences of chemotherapy ± radiotherapy may jeopardise the long term survival of a substantial proportion of patients cured of this disease [22] . Randomised trials suggest that anthracycline containing chemotherapy regimens are superior in terms of failure free survival to MOPP alone and that ABVD is equivalent to alternating MOPP/ABVD [2, 3] . ABVD has been recommended as the standard therapy for advanced stage Hodgkin's disease not only because of its improved efficacy, but also because it causes less acute and chronic myelotoxicity and is much less likely to cause infertility than alternating or hybrid regimens [2] . Although the cumulative doses of doxorubicin and bleomycin used in this regimen may cause acute and/or chronic cardiopulmonary toxicities, the relatively short follow up in most reported studies in adults does not enable an accurate estimate of these risks to be made.
The issue of cardiotoxicity is of great importance as long term follow up of survivors of paediatric malignancies treated with anthracyclines has demonstrated abnormalities of cardiac function in 25%-57% of patients studied [23, 24] . The incidence appears to increase with time and is related to the cumulative dose and dose intensity of anthracycline received [24] . Whether adults are less susceptible to the late cardiac toxicity induced by doxorubicin is uncertain. In a randomised study comparing treatment with 6 cycles of ABVD or MOPP given together with radiotherapy the Milan group found no clinically significant difference in post treatment cardiac or pulmonary function between the two groups in a total of 50 patients [5] . Similarly, the EORTC H6U trial which compared ABVD or MOPP + mantle radiotherapy demonstrated no change in the mean left ventricular ejection fraction in either group after treatment [4] .
ABVD may also affect pulmonary function. In the CALGB study [2] , clinically important severe pulmonary toxicity occurred in 6% of the ABVD group and 3 patients (all > 40 years) died of pulmonary toxicity. Similar toxicities have been reported in other large studies [4, 25] . In a retrospective review of 116 patients aged under 50 years with supradiaphragmatic Hodgkin's disease treated with thoracic radiotherapy alone or combined modality therapy, who had been in CR for > 5 years at the time of follow up, nearly 30% of patients were found to suffer from dyspnoea on exertion associated with a restrictive ventilatory impairment and a reduction in gas transfer. Chemotherapy containing bleomycin-anthracyclines was the only significant predictor for lung function reduction on multivariate analysis [15] . However, in a prospective analysis at Stanford University [26] which compared the effects on lung function of mediastinal radiotherapy, mediastinal radiotherapy + bleomycin containing chemotherapy and bleomycin containing chemotherapy alone, mantle radiotherapy was the only significant treatment variable predictive of changes in pulmonary function.
PACE BOM is an intensive regimen which shortens the duration of treatment for advanced Hodgkin's disease to 12 weeks. Dose intensity is maintained by administering alternating weekly cycles of myelosuppressive and nonmyelosuppressive drugs, rapidly exposing the tumour to multiple active drugs. This regimen was designed to reduce the potential for late cardiac and pulmonary toxicity and secondary acute leukemia by using lower cumulative doses of doxorubicin (210 mg/ m 2 compared with 300-400 mg/m 2 in ABVD), bleomycin (60 mg/m 2 compared with 120-160 mg/m 2 in ABVD) and cyclophosphamide (1800 mg/m 2 ). Etoposide has been shown to have marked activity as a single agent in relapsed Hodgkin's disease [27, 28] and its incorporation into the PACE BOM regimen allowed a reduction in the dose of doxorubicin. Since this regimen was designed, concern has been raised about the association between etoposide and the development of secondary acute myeloid leukaemia. The risk appears to be related to the the cumulative dose of etoposide and also to the administration schedule with those receiving twice weekly or weekly etoposide and cumulative doses >2 g/m 2 at greatest risk [29, 30] . The dose of etoposide used in PACE BOM is relatively low (900 mg/m 2 ) and it is given once every 2 weeks, so it is unlikely to cause such problems, although clearly careful future monitoring is required. There is limited data on the activity of methotrexate as a single agent in Hodgkin's disease, however it has been successfully incorporated into the vinblastine, bleomycin, methotrexate (VBM) regimen used in early stage Hodgkin's disease [31, 32] . Intravenous cyclophosphamide has been used in place of mustine in the MOPP regimen. This drug is known to be active in Hodgkin's disease and at the dose used in the PACE BOM regimen appears to cause little or no gonadal toxicity.
The role of radiotherapy in the management of patients with advanced Hodgkin's disease remains unclear. The benefit of consolidative irradiation in patients with advanced disease who achieve a CR with chemotherapy is unproven. Several large retrospective studies have suggested that the relapse rate may be lower in patients receiving irradition to previous sites of disease after acheiving a CR following chemotherapy [33, 34] , but randomised trials using adequate chemotherapy have failed to confirm that there is a benefit and concern exists over the potential for increased toxicity with combined modality therapy (CMT). The Southwest Oncology Group (SWOG) randomised 278 patients with stage III/IV Hodgkin's disease who achieved a CR after 6 cycles of nitrogen mustard, vincristine, prednisolone, bleomycin, doxorubicin and procarbazine (MOP-BAP) to no further treatment or low dose radiation (2000 cGy to lymph node areas and 1000-1500 cGy to other involved organ sites) to all initially involved sites [35] . There was no significant difference in remission duration, relapse free survival or overall survival between the 2 groups. Similarly, the German Hodgkin's Study Group randomised 171 patients who achieved a CR following treatment with 3 x (COPP + ABVD) to receive either 2000 cGy radiotherapy to initially involved sites of disease or to an additional 1 x (COPP + ABVD) and found no statistically significant difference in efficacy between these approaches [36] .
However, for those patients who present with bulky mediastinal disease, most investigators agree that CMT is the treatment of choice based on retrospective studies showing a significant improvement in disease free survival [37, 38] . In addition, a subgroup analysis in the SWOG study suggested improved remission duration following CMT in patients with bulky mediastinal nodular sclerosing Hodgkin's disease [35] . In view of the uncertainty regarding the benefits of CMT we limited the use of consolidative irradiation to patients with large mediastinal masses who had a persisting abnormality in the mediastinum which was visible on chest X-ray after the completion of chemotherapy as we were concerned about the potential late toxicity of CMT, particularly cardiac disease and pulmonary fibrosis and wished to restrict the use of consolidative irradiation to those patients at highest risk of relapse. The radiotherapy field was restricted to the mediastinum ± contiguous sites of nodal disease which were involved at presentation and the radiation dose to 36-40 Gy as it has previously been reported that the risk of late cardiac complications is greatest in patients receiving > 40 Gy [14] .
Despite a relatively short period of follow up, our results with PACE BOM +/-radiotherapy for patients with stage III/IV Hodgkin's disease (73% 5-year actuarial FFS) are comparable to those achieved with other anthracycline based regimens. However, for patients with stage II disease who form the largest group (52%) in this study, the outcome is considerably worse than expected, with a 5-year actuarial FFS of only 52%. This may be due to underutilization of radiotherapy, but even in those patients with bulky mediastinal disease who received consolidative radiotherapy, 6 of 13 (46%) have relapsed, 5 of these within the radiation field, suggesting that differences in the chemotherapy regimen and/or our patient population may also account for this result.
The major acute toxicities that occurred with PACE BOM chemotherapy were mucositis, most likely secondary to methotrexate, and cutaneous toxicity due to bleomycin. The incidence of neutropenia was similar to that reported with ABVD [2] and infectious complications were uncommon, probably due to the use of prophylactic cotrimoxazole. In the 28 patients we evaluated, gonadal function was preserved in the majority. We did not observe any acute cardiac or pulmonary toxicity; follow-up is too short to comment on late complications.
In recent years a number of clinical trial groups have developed comparable treatment approaches to PACE BOM. The Stanford V regimen (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide and prednisolone) [18] is a similar alternating chemotherapy approach which has been reported to produce superior results in a similar group of patients to those described here with the exception that none had received prior radiotherapy. The difference in results is most striking for those patients with bulky stage II disease who had 100% FFS at 3 years in the Stanford series, which is superior to previously published results [38] [39] [40] [41] . The total doses of doxorubicin, bleomycin and etoposide and thus the dose intensity of these drugs is less in the Stanford V regimen, but it includes vinblastine and mechlorethamine at a relatively higher single dose than the cyclophosphamide used in PACE BOM. There are also significant differences in the radiotherapy which was administered to patients following Stanford V compared with PACE BOM. All patients with bulky mediastinal disease received consolidative irradiation to a mantle or modified mantle field and any contiguous extralymphatic sites (including lung, pleura and pericardium) following chemotherapy irrespective of whether they had already achieved a CR/CRu. In addition, radiotherapy was given to all other sites of initial tumour bulk, defined as disease > 5 cm in horizontal diameter. Only 31% of eligible patients in our series received consolidative radiotherapy compared with 89% in the Stanford V group. The more frequent and extensive use of radiotherapy in the Stanford series may explain their superior results in patients with bulky stage II disease.
The Royal Marsden Hospital have recently reported their results with the VEEP regimen (vincristine, epirubicin, etoposide and prednisolone) [42] in a similar patient population to our own. This regimen was given on days 1 and 8 of a 3-week cycle with responding patients receiving treatment for 2 cycles beyond CR. The median number of cycles given was 6 (range 3-10). Epirubicin was substituted for doxorubicin because of anticipated lower rates of cardiac toxicity. Adjuvant radiotherapy was considered for stage I and II patients with bulky mediastinal masses (> 5 cm) at diagnosis or those with localized radiologic abnormalities suspicious of residual disease on completion of chemotherapy. However, no information was given as to the fields or doses used. With a similar duration of follow up, the results in terms of CR rate, OS and FFS are very similar to those with PACE BOM +/-radiotherapy.
Our results with the PACE BOM regimen together with those of Stanford V and VEEP [18, 42] support the concept that brief intensive chemotherapy regimens can be effectively delivered together with consolidative irradiation to patients with advanced Hodgkin's disease with acceptable toxicity and efficacy. In a non randomised comparison these regimens appear comparable to standard treatment such as ABVD. The duration of follow up is as yet too short to determine the long term toxicity of these regimens but there are good reasons to believe that fertility can be preserved and cardiopulmonary toxicity and second malignancies will be reduced. The advantages to patients of completing treatment more quickly are considerable, but ultimately survival and FFS are the most important end points. Regimens such as PACE BOM should now be compared in randomised trials with standard anthracycline based chemotherapy regimens in patients with advanced Hodgkin's disease.
